Tag: RNS60

Revalesio Announces the Design of RESCUE, a Phase 2 Trial of RNS60 in Acute Ischemic Stroke, and the Presentation of Preclinical Data at the International Stroke Conference 2022

TACOMA, Wash.–(BUSINESS WIRE)–Revalesio, a clinical-stage pharmaceutical company developing treatments for neurological diseases, presented the design of its recently launched RESCUE Phase 2 clinical trial evaluating RNS60 as a treatment for large vessel occlusion acute ischemic stroke (AIS), as well as new preclinical data supporting the advancement of RNS60 for AIS. […]